ZYMEWORKS INC (ZYME) Stock News

USA - NASDAQ:ZYME - US98985Y1082 - Common Stock

19.38 USD

+0.08 (+0.41%)

Last: 10/29/2025, 8:07:03 PM

19.5 USD

+0.12 (+0.62%)

After Hours: 10/29/2025, 8:07:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ZYME Latest News, Press Relases and Analysis

All

Press Releases

17 hours ago - By: Zacks Investment Research

Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know

2 days ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

2 days ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

6 days ago - By: Benzinga

5 Analysts Have This To Say About Zymeworks

7 days ago - By: Zymeworks Inc.

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

7 days ago - By: Zymeworks Inc.

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

14 days ago - By: Zymeworks Inc.

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

14 days ago - By: Zymeworks Inc.

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

17 days ago - By: Zymeworks Inc.

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

17 days ago - By: Zymeworks Inc.

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

21 days ago - By: Zymeworks Inc.

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

21 days ago - By: Zymeworks Inc.

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

2 months ago - By: Stocktwits - Mentions: VFMO IWMW

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research - Mentions: CRMD KOD ALVO

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

3 months ago - By: Zacks Investment Research - Mentions: CRMD IMVT ALVO

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

3 months ago - By: Zacks Investment Research

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

3 months ago - By: Zymeworks Inc.

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

3 months ago - By: Zymeworks Inc.

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

3 months ago - By: Zacks Investment Research - Mentions: BRTX

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

3 months ago - By: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Zymeworks Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

3 months ago - By: Zymeworks Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

3 months ago - By: Zymeworks Inc.

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

3 months ago - By: Zymeworks Inc.

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025